AAKP's role in Clinical Trials and Market Research
AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice and experience with renal companies and clinical trials - to create more and better treatment options for kidney patients, so they can achieve their aspirations.
You may have heard the term “clinical trials” but wonder what that means. Is a clinical trial something you can participate in? What do you need to do to get started? We have pulled together some information that you might find helpful as you decide whether you would like to participate in a clinical trial.
Clinical Trials and Market Research Opportunities
Below is a list of the Clinical Trials and Market Research opportunities that AAKP is partnering to raise awareness of. You can also use the search tool below to be matched to even more opportunities.
| Name | Description | Learn More |
|---|---|---|
| AFFINITY Study | The AFFINITY Study is an open-label, phase 2 study evaluating an investigational medication called atrasentan in patients with immunoglobulin A nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease (DKD). The goal of the AFFINITY Study is to understand whether atrasentan can lower the amount of protein in the urine and slow the decline of kidney function in patients. Approximately 80 patients will receive atrasentan by mouth for 52 weeks. Virtual trial options may include telemedicine and home health nurse visits. | Click here to read more about this opportunity. |
| BION-1301 Study | The clinical trial will evaluate the safety and how the body and immune system respond to an investigational medication called BION-1301*, a potential treatment for patients diagnosed with IgAN. There are currently no FDA/MHRA approved treatments for IgAN, an autoimmune disease. BION-1301 has the potential to work by decreasing the amount of autoimmune proteins in your kidney that can lead to or worsen IgAN. BION-1301 will be administered subcutaneously to all patients for a total treatment period of 52 weeks. | Click here to read more about this opportunity. |
| ALIGN Study | This study is testing an investigational medication, called atrasentan, that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with IgA nephropathy (IgAN). | Click here to read more about this opportunity. |
| Kibow Pharmaceuticals (Phase 2B study of US- APR 2020) | The purpose of this study to evaluate the safety and efficacy of an investigational medication in individuals with chronic kidney disease stage 4. This purpose of this FDA-approved Investigational drug is to determine safety and its ability to reduce or slow progression of patients who have been diagnosed with CKD stage 4 and how it impacts on their quality of life. | Click here to read more about this opportunity. |
| TRACTION-2 Study | The TRACTION-2 clinical research trial is evaluating an investigational product called GFB-887 for the potential treatment of focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), and diabetic nephropathy (DN). The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to their kidney disease. | Click here to read more about this opportunity. |
| InnAVasc Arteriovenous Graft Technology | If you have kidney failure and are currently undergoing hemodialysis or are expected to require hemodialysis, you may be a candidate for a clinical study evaluating the InnAVasc Arteriovenous Graft – an investigational graft that may make the graft easier to locate under your skin, safer to stick for dialysis, more durable, less likely to bleed after your dialysis session when compared to standard care grafts, and allows for immediate use to reduce catheter time. | Click here to read more about this opportunity. |
| TruGraf Long Term Clinical Outcomes Study | The purpose of this study is to evaluate the impact of serial monitoring renal transplant patients with both TruGraf® and TRAC™ on long term outcomes. | Click here to read more about this opportunity. |
| FALCON Study | FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with ADPKD. The investigational drug, study-related procedures, and doctor visits will be provided at no cost. Visit PKDstudy.com for more information. | Click here to read more about this opportunity. |
| Emerald Study | Ongoing Pediatric Clinical Trial. Parents – do you have a child between the ages of 2 and 12 with kidney disease who also struggles to manage high blood potassium levels? | Click here to read more about this opportunity. |
